08:34 AM EDT, 03/21/2024 (MT Newswires) -- Knight Therapeutics Inc. ( KHTRF ) , a pan-American (ex-US) specialty pharmaceutical company, on Thursday announced its Q4 2023 results.

The company reported a 9% YoY decrease in quarterly revenue, from $81.65 million, to $74.2 million.

Net loss was $24.3 million, compared with 15.2% last year, a 60% increase.

Knight reported that or the quarter ended December 31, 2023, excluding the impact of hyperinflation, revenues increased by $4.6 million, or 5% compared to the same period in prior year. The appreciation of select LATAM currencies led to an increase in revenues of $5.2 million in Q4 2023 compared with last year, the statement noted.